Equites Radar

IRTC · iRhythm Holdings, Inc.

Medical DevicesUnited StatesAnalyst view: Strong Buy

$109.20

+4.65% last session

End-of-day data · updated 2026-07-28

Mildly bearish1 bullish · 3 bearish technical signals
Consensus: Strong Buy (1.13 from 14 analysts)
To mean target: +62.2%

Market cap

$4B

Enterprise value

$4B

Trailing P/E

Forward P/E

103.7

Dividend yield

Beta

1.27

Avg volume

1M

Employees

2K

2D change

5D change

4.16%

10D change

1.15%

30D change

-5.67%

60D change

-1.54%

MTD change

-9.94%

YTD change

-36.80%

Analyst Outlook

Consensus ratingStrong Buy
Recommendation mean (1–5)1.13
Covering analysts14
Mean price target$177.07
Low price target$150.00
Upside to mean target+62.2%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)54.3
50-day MA$113.60
200-day MA$142.88
Price vs 50-day MA+3.3%
Price vs 200-day MA-17.9%
MACD histogram-0.48
Volume vs 3-month avg0.9×
52w low $101.7952w high $189.25

Analyst sentiment over time — IRTC

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-07-23

Latest call per bank · past 12 months

Bank of America

Buy

$180

+64.8% vs price
▼ cut from $225Maintains · 2026-05-18

Citigroup

Buy

$157

+43.8% vs price
▲ raised from $155Maintains · 2026-05-04

JP Morgan

Overweight

$175

+60.3% vs price
▼ cut from $215Maintains · 2026-05-01

Wells Fargo

Overweight

$180

+64.8% vs price
▼ cut from $200Maintains · 2026-05-01

Goldman Sachs

Neutral

$147

+34.6% vs price
▼ cut from $184Maintains · 2026-04-09

Morgan Stanley

Overweight

$205

+87.7% vs price
▲ raised from $195Maintains · 2025-12-02

Recent rating actions

DateFirmActionRatingPrice target
2026-07-23Stephens & Co.InitiatesOverweight$0.00 $160
2026-07-16Truist SecuritiesMaintainsBuy$174 $160
2026-07-06Evercore ISI GroupMaintainsOutperform$160 $150
2026-06-22BTIGReiteratesBuy$185
2026-06-10BTIGReiteratesBuy$185
2026-06-01Canaccord GenuityMaintainsBuy$180 $152
2026-05-18Bank of AmericaMaintainsBuy$225 $180
2026-05-04CitigroupMaintainsBuy$155 $157

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-07-28

  • RSI (14): RSI is 54 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 3.3% above the 50-day MA ($113.60).
  • Price vs 200-day MA: Trading 17.9% below the 200-day MA ($142.88).
  • MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
  • MACD (12,26,9): MACD histogram is negative (-0.48) — short-term momentum is fading.
  • 52-week range: Price sits between the 52-week low ($101.79) and high ($189.25).

IRTC Price Chart

Loading chart for IRTC

Fundamentals

Revenue (TTM)$1.0B
EBITDA$0M
Free cash flow$0M
Operating cash flow$0M
Book value / share$4.91
Net debt / EBITDA-16.1
WACC11.0%
Revenue growth26.00%
Earnings growth

About iRhythm Holdings, Inc.

iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

More in Medical Devices

Screen IRTC against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.